ProQR Therapeutics (PRQR) Research & Development (2012 - 2026)

ProQR Therapeutics (PRQR) has reported Research & Development for 15 consecutive years, with $13.5 million the latest figure, recorded in Q1 2026.

• Quarterly Research & Development fell 4.0% year-over-year to $13.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.4 million (up 18.85% YoY) and the FY2025 annual result came in at $50.9 million, up 23.04% from the prior year.
• Research & Development slipped to $13.5 million in Q1 2026 per PRQR's latest filing, from $90.5 million in the prior quarter.
• Over the last five years, Research & Development for PRQR reached as high as $103.6 million in Q4 2022 and fell as low as -$17.5 million in Q3 2022.
• A 5-year average of $13.0 million and a median of -$6.9 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development surged 830.85% — and 2024, when it plunged 72.86%.
• Year by year, Research & Development stood at $103.6 million in 2022, then tumbled by 53.25% to $48.4 million in 2023, then soared by 45.9% to $70.7 million in 2024, then rose by 28.09% to $90.5 million in 2025, then slumped by 85.13% to $13.5 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $13.5 million, $90.5 million, and -$12.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.